Back to Results
First PageMeta Content
Immune system / Health / Treatment of multiple sclerosis / Interferon beta-1a / Interferon / Neuromyelitis optica / McDonald criteria / Diagnostic criteria for MS / Natalizumab / Multiple sclerosis / Medicine / Autoimmune diseases


Microsoft Word - Immunomod.doc
Add to Reading List

Document Date: 2011-04-18 09:33:24


Open Document

File Size: 1,46 MB

Share Result on Facebook

City

Hannover / Dresden / Hennigsdorf / Bern / Rostock / Windsheim / Munich / Vancouver / Vienna / Hamburg / Sevilla / Geneva / Frankfurt/Main / Düsseldorf / Ludwigshafen / Zurich / Berlin / Reykjavik / Mannheim / Cologne / Stuttgart / Prague / Lausanne / Wermsdorf / Brussels / /

Company

IgG / Biogen Idec / Schering / Multiple Sclerosis Therapy Consensus Group / /

Country

Switzerland / Hungary / Norway / Iceland / Finland / Germany / Croatia / Italy / Belgium / Austria / Spain / Greece / Czech Republic / /

/

Event

FDA Phase / /

Facility

Neurology University of Würzburg Josef-Schneider-Str. / /

IndustryTerm

important paraclinical diagnostic tool / Multiple Sclerosis Therapy / treatment of MS / Therapy of Multiple Sclerosis / therapy of MS / diagnostic algorithm / spinal cord imaging / healthcare provisions / /

MedicalCondition

antibody-associated disease / Multiple Sclerosis / disease modifying drug / vasculitis / clinically isolated syndrome / chronic infections / diseases / disorders / inflammatory CSF syndrome / Devic’s syndrome / neuromyelitis optica / MS / autoimmune diseases / disease / early spontaneous abortions / longitudinally extensive transverse myelitis / paraneoplastic syndromes / /

MedicalTreatment

immunotherapy / contraception / /

Organization

FRCP Department / American Academy of Neurology / European Federation of Neurological Societies / European Union / Neurology University of Würzburg Josef-Schneider-Str. / European Medicines Agency / Writing committee / /

Person

K. Lowitzsch / S. Bergmann / F. Deisenhammer / C. Kleinschnitz / A. Orologas / D. Pöhlau / S. Schmidt / Klaus V. Toyka / T. Berger / M. Myhr / P. Oschmann / O. Neuhaus / R. Gold (Bochum) / E. Stark (Offenbach) / M. Freimüller / B. Wildemann / M. Götschi-Fuchs / M. Pette / B. Kallmann / W.G. Elias / G. Schock / G. Japp / B. C. Kieseier / N. König / U. Manegold / M. Heibel / P. Hartung / L. Kappos / K. Ruprecht / H. Tumani / J. Mertin / D. Dommasch / J. Köhler / W. Kölmel / T. Henze / V. Leussink / S. Strasser-Fuchs / M. Buttmann / S. Bamborschke / H. Wiethölter / U. Buettner / F. Fazekas / J. Kesselring / T. Ziemssen / W. Brück / A. Guseo / E. Fasshauer / Ralf Gold / K. Baum / Peter Rieckmann / C.Heesen / P. Haller / G. Izquierdo / S. Jung / H. Markut / S. Schwarz / M. Mäurer / G. Schwendemann / F. Heidenreich / Reinhard Hohlfeld / A. Bayas / R. Benecke / M. Schluep / A. Steinbrecher / A. Chan / S. Podobnik / W. Köhler / M. Schulz / M. Pugliatti / H. Schipper / Heinz Wiendl / G. Haferkamp / D. Seidel / Hans-Peter Hartung / M. Stangel / I. Elovaara / /

/

Product

IFN-β medication / Avonex / Tysabri / Rebif / Betaseron / Betaferon® / EMEA / /

ProvinceOrState

Montana / Mississippi / /

Technology

diagnostic algorithm / antibodies / MRI / /

SocialTag